Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
1 "Maintenance treatment"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis
Satoshi Yamada, Takuya Yoshino, Minoru Matsuura, Masamichi Kimura, Yorimitsu Koshikawa, Naoki Minami, Takahiko Toyonaga, Yusuke Honzawa, Hiroshi Nakase
Intest Res 2015;13(3):250-258.   Published online June 9, 2015
DOI: https://doi.org/10.5217/ir.2015.13.3.250
AbstractAbstract PDFSupplementary MaterialPubReader
<b>Background/Aims</b><br/>

The long-term clinical outcomes of patients with bio-naive ulcerative colitis (UC) who maintain remission with thiopurine are unclear. The aim of this study was to assess the long-term efficacy and safety of maintenance treatment with thiopurine in UC patients.

Methods

This was a retrospective observational cohort analysis conducted at a single center. Between December 1998 and August 2013, 59 of 87 patients with bio-naive UC who achieved remission after induction with treatments other than biologics were enrolled. Remission maintenance with thiopurine was defined as no concomitant treatment needed other than 5-aminosalicylate without relapse. We assessed the remission-maintenance rate, mucosal healing rate, colectomy-free rate, and treatment safety in UC patients who received thiopurine as maintenance treatment.

Results

The 84-month cumulative remission-maintenance and colectomy-free survival rates in the UC patients who were receiving maintenance treatment with thiopurine and 5-aminosalicylate were 43.9% and 88.0%, respectively. Of the 38 patients who underwent colonoscopy during thiopurine maintenance treatment, 23 (60.5%) achieved mucosal healing. Of the 59 patients who achieved clinical remission with thiopurine, 6 patients (10.2%) discontinued the thiopurine therapy because of adverse events.

Conclusions

Our study demonstrates the long-term efficacy and safety of thiopurine treatment in patients with bio-naive UC.

Citations

Citations to this article as recorded by  
  • cGAS-STING signaling: a therapeutic target in inflammatory bowel disease and related colorectal cancer
    Xi Chen, Xiaohua Tang, Sixuan Chen, Yang Ye, Fei Mao
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
    Mukesh Kumar Ranjan, Peeyush Kumar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Sandeep K Mundhra, Rithvik Golla, Shubi Virmani, Raju Sharma, Peush Sahni, Prasenjit Das, Mani Kalaivani, Ashish Datt Upadhyay, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Journal of Crohn's and Colitis.2024; 18(2): 192.     CrossRef
  • Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
    Makoto Naganuma, Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Toshiyuki Matsui, Yasuo Suzuki, Lyann Ursos, Shigeru Sakamoto, Mitsuhiro Shikamura, Tetsuharu Hori, Jovelle Fernandez, Mamoru Watanabe, Toshifumi Hibi, Takanori Kanai
    Journal of Gastroenterology and Hepatology.2022; 37(1): 81.     CrossRef
  • Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
    Satohiro Matsumoto, Hirosato Mashima
    Crohn's & Colitis 360.2021;[Epub]     CrossRef
  • Treatment of Inflammatory Bowel Disease: A Comprehensive Review
    Zhaobei Cai, Shu Wang, Jiannan Li
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
    Hiroshi Nakase
    Gut and Liver.2020; 14(1): 7.     CrossRef
  • The Leading Edge of the Treatment of Inflammatory Bowel Disease
    Hiroshi Nakase
    Nihon Naika Gakkai Zasshi.2020; 109(6): 1145.     CrossRef
  • Predictive Role of NUDT15 Variants on Thiopurine-Induced Myelotoxicity in Asian Inflammatory Bowel Disease Patients
    Natalia Sutiman, Sylvia Chen, Khoon Lin Ling, Sai Wei Chuah, Wai Fook Leong, Vinayak Nadiger, Madeline Tjai, Chris San Choon Kong, Brian John Schwender, Webber Chan, Hang Hock Shim, Wee Chian Lim, Chiea Chuen Khor, Yin Bun Cheung, Balram Chowbay
    Pharmacogenomics.2018; 19(1): 31.     CrossRef
  • NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
    Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura
    Intestinal Research.2017; 15(3): 328.     CrossRef
  • Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
    Yoon Jee Lee, Jae Hee Cheon, Jae Hyun Kim, SunHo Yoo, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim
    Yonsei Medical Journal.2017; 58(1): 144.     CrossRef
  • Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study
    Caroline Prieux-Klotz, Stéphane Nahon, Aurelien Amiot, Leila Sinayoko, Carole Galéano-Cassaz, Stanislas Chaussade, Romain Coriat, Pierre Lahmek, Vered Abitbol
    Digestive Diseases and Sciences.2017; 62(2): 473.     CrossRef
  • Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission
    Jae Hyun Kim, Jae Hee Cheon, Yehyun Park, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim
    Scandinavian Journal of Gastroenterology.2016; 51(9): 1069.     CrossRef
  • Is Long-Term Therapy With Thiopurines Effective for Maintaining Remission in Patients With Moderate-To-Severe Ulcerative Colitis?
    Seong Ran Jeon, Won Ho Kim
    Intestinal Research.2015; 13(3): 191.     CrossRef
  • 7,762 View
  • 66 Download
  • 13 Web of Science
  • 13 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP